Seoul Bio Hub announced on the 9th that it is recruiting bio startups to participate in the '2025 Bio Open Innovation Chain' until September 30th.
The "Bio Open Innovation Chain" is a growth chain program designed to help startups increase their technological maturity through technological collaborations with domestic innovative companies, ultimately expanding into joint research and technology transfers with global pharmaceutical companies. This year, the program will focus on strengthening collaborations between startups and domestic innovative companies, supporting them to enhance technological maturity and corporate value prior to entering the global market. The program will be operated in collaboration with the Korea Innovative Medicine Consortium (KIMCo).
Participating companies will be provided with a variety of practical support, going beyond simple partner matching to ensure tangible results from their collaborations. First, pre-event expert consulting tailored to the technological needs of large companies will be provided, and meetings with executives from innovative companies will be arranged to facilitate collaborative discussions. Investment connections with Seoul Bio Fund management companies and major bio venture capital firms will also be pursued.
Innovative companies participating in this year's collaboration include Dong-A ST, Liga Chem Bio, ABL Bio, Olix, Genome & Company, T&L, and Huons. These companies are seeking promising partners in diverse fields, including antibody and ADC platforms, siRNA delivery technologies, and microbiome-based technologies. Investors include CKD Venture Capital, LSK Investment, Daekyo Investment, Scaleup Partners, Solidus Investment, Shinhan Venture Investment, and Aju IB Investment.
In addition, KIMCo, a collaboration platform representing domestic pharmaceutical companies, will promote technological collaboration with companies such as Yuhan Corporation, LG Chem, GC Pharma, Hanmi Pharmaceutical, and HK inno.N when discovering promising startups, and will also make direct investments in some companies.
The selected startups will participate in the '2025 Seoul Bio-Medical Open Collaboration' event held at Seoul Bio Hub on November 26th, where they will have the opportunity to have 1:1 partnering meetings with innovative companies and make corporate presentations (IR).
Kim Hyun-woo, director of Seoul Bio Hub, said, “This program is a model designed with a step-by-step chain structure to ensure that innovative technologies can grow within the domestic bio ecosystem and lead to global cooperation.” He added, “This year, we will support the solidification of the foundation for cooperation between startups and domestic innovative companies, thereby establishing a bridgehead for global expansion.”
- See more related articles
You must be logged in to post a comment.